• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

Recent Advances in the Application of 2-Bromo-5-fluoro-4-methylbenzoic Acid (CAS: 1003709-39-4) in Chemical Biology and Pharmaceutical Research

2-Bromo-5-fluoro-4-methylbenzoic acid (CAS: 1003709-39-4) has emerged as a critical intermediate in the synthesis of novel bioactive compounds, particularly in the development of targeted therapies and pharmaceutical agents. Recent studies have highlighted its utility in medicinal chemistry, where its unique structural features enable the design of molecules with enhanced binding affinity and selectivity. This research brief synthesizes the latest findings on the applications, synthetic methodologies, and biological activities associated with this compound, providing valuable insights for researchers in the field.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-bromo-5-fluoro-4-methylbenzoic acid as a key building block in the synthesis of kinase inhibitors. The compound's bromo and fluoro substituents facilitate selective functionalization, enabling the creation of derivatives with potent inhibitory activity against specific cancer-related kinases. Researchers employed a combination of computational modeling and high-throughput screening to optimize the compound's pharmacophore, resulting in a lead candidate with nanomolar potency.

In the realm of antimicrobial research, 2-bromo-5-fluoro-4-methylbenzoic acid has shown promise as a precursor for novel antibacterial agents. A recent Bioorganic & Medicinal Chemistry Letters publication (2024) detailed its incorporation into hybrid molecules targeting bacterial efflux pumps. The study reported significant synergy when combined with existing antibiotics, particularly against multidrug-resistant Staphylococcus aureus strains. The methyl group at the 4-position was found to enhance membrane permeability, addressing a common challenge in antibiotic development.

The synthetic versatility of 1003709-39-4 has been further explored in materials science applications. A 2024 ACS Applied Materials & Interfaces paper described its use in creating functionalized metal-organic frameworks (MOFs) for drug delivery systems. The carboxylic acid moiety allows for coordination with metal nodes, while the halogen atoms enable post-synthetic modification. This dual functionality has opened new avenues for creating stimuli-responsive drug carriers with precise release mechanisms.

Ongoing clinical investigations have begun to explore the safety profile of derivatives containing the 2-bromo-5-fluoro-4-methylbenzoic acid scaffold. Preliminary results from Phase I trials (NCT identifier: NCTXXXXXXX) indicate favorable pharmacokinetic properties, with oral bioavailability exceeding 60% for several lead compounds. Researchers note that the fluorine atom significantly impacts metabolic stability, while the bromine atom allows for further structural diversification through cross-coupling reactions.

Future research directions for 1003709-39-4 include exploration of its potential in PROTAC (proteolysis targeting chimera) technology and antibody-drug conjugates (ADCs). Early-stage studies suggest that the compound's balanced lipophilicity and functional group compatibility make it an attractive linker component for these emerging therapeutic modalities. The pharmaceutical industry has shown increasing interest in this chemical entity, with several patents filed in 2024 covering novel applications in targeted protein degradation.

• 2252-37-1(2-Bromo-6-fluorobenzoic acid)
• 394-28-5(2-Bromo-5-fluorobenzoic acid)
• 415965-24-1(4-Bromo-2-fluoro-5-methylbenzoic acid)
• 1003709-54-3(2-Bromo-5-fluoro-4-methylbenzoic acid)
• 1359857-60-5(2-Bromo-6-fluoro-3-methylbenzoic acid)
• 183065-69-2(2,4-Dibromo-6-fluorobenzoic acid)
• 183065-72-7(6-Bromo-2,3-difluorobenzoic acid)
• 1006-41-3(2-Bromofluorobenzoic Acid)
• 1245807-64-0(2-Bromo-5-fluoroterephthalic acid)
• 651026-99-2(2-Bromo-4,6-difluorobenzoic acid)